Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea,” or the “Company”), a clinical-stage precision oncology company, has achieved a significant milestone. The first patient has been dosed at Dose Level 7, evaluating ATRN-119 550 mg twice daily, in the ongoing ABOYA-119 Phase 1/2a clinical trial. This marks a crucial step in our journey, and we are excited to share this progress with you. Let’s delve into the value of this development, especially in the context of the ever-evolving landscape of cancer and therapies.
Given the complexity of the therapies for accuracy. I need to use some press release stuff so investors can get their interest peak and add a portfolio.
Aprea is at the forefront of a new approach to treating cancer. We are leveraging the vulnerabilities of cancer cell mutations to develop a technology that not only kills tumours but also minimizes the impact on normal, healthy cells. This approach, with its potential applications across multiple cancer types, is a game-changer. It enables us to target a wide range of tumours, from ovarian and colorectal to prostate and breast cancers
, significantly expanding the scope of our impact.
Aprea’s lead programs, APR-1051 and ATRN-119, are at the forefront of our clinical development for solid tumor indications. These programs hold great promise for the future of cancer treatment. For more information, please visit our website at www.aprea.com and follow us on LinkedIn or X. The following is the pipe4lind, which, when coupled with biotech, is exciting, to say the least. The third top line drives down into the relevant cancers targeted.
1 RepliBiom – a synthetic lethality discovery platform
Our Lead Programs: ATR inhibitor, ATRN-119, and WEE1 inhibitor, APR-1051
Our novel macrocyclic ATR inhibitor, ATRN-119, and our next-generation inhibitor of the WEE1 kinase, APR-1051, are the cornerstones of our synthetic lethality-based cancer therapeutics pipeline. These Aprea drugs were internally discovered, developed, and evaluated by our dedicated team of chemists, scientists, and clinicians.
At Aprea, we understand that the issue of toxicity is a significant concern in cancer therapies. That’s why our lead programs, ATRN-119 and APR-1051, are designed with a strong focus on minimizing toxicity, and ensuring the safety of our patients.
Our novel macrocyclic ATR inhibitor, ATRN-119, and our next-generation inhibitor of the WEE1 kinase, APR-1051, are the cornerstones of our synthetic lethality-based cancer therapeutics pipeline. These Aprea drugs were internally discovered, developed, and evaluated by Apre’s dedicated chemists, scientists, and clinicians. This advance is just one of the advanced developmental biotech APRE.
Today, Aprea Therapeutics is a clinical-stage, platform biotechnology company focused on the development of novel, synthetic lethality-based therapies with direct, on-target mechanisms of action and clear clinical pathways.
Aprea Therapeutics acquired privately held Atrin Pharmaceuticals in May 2022. We have made the assets and technology acquired from Atrin a key focus moving forward. Our approach involves targeting the ATR pathway (ataxia telangiectasia and Rad3-related) to limit the ability of tumour cells to engage their DNA damage and response pathways (DDR). This targeted strategy may significantly reduce the treatment resistance of cancer cells, providing a clear scientific basis for our approach.
Apres toi.
